ABSTRACT Studies have established that cryoprecipitates of
Transformation-enhancing factors (TEF) have been shown to be present in the culture media of tumor virus-transformed cells and of spontaneously transformed established cell lines. TEF activity is detected as promotion of the morphological transformation ofchicken embryo fibroblasts infected by Rous sarcoma virus or its temperature-sensitive mutants (1, 2) . Moreover, TEF activity has been found in vivo in human plasma cryoprecipitates from patients affected with different neoplastic diseases (leukemia, lymphoma, and solid tumors) but not in healthy controls or in patients with nonneoplastic diseases (3) . TEF activity in plasma cryoprecipitate appears to have potential diagnostic and prognostic value (4) . In some tumor patients, TEF activity is detectable in whole plasma, but fractionation of plasma into the cryoprecipitate and its supernatant is an effective means to separate TEF activity (which is greatly enriched in the cryoprecipitate) from transformation-inhibiting factors (TIF) (which are mainly detected in the supernatant) (3) .
Although the molecular identities of TEF and TIF activities have not been defined, it has been proposed that proteins involved in blood coagulation may posses TIF activity, whereas enzymes and breakdown products of fibrinolysis may posses TEF activity (3) . That TIF activity may be assigned to some of the proteins involved in blood coagulation has been demonstrated (5) . In this study, we tested components and products of fibrinolysis for TEF activity. Among the reasons that led us to look for TEF activity in fibronectin degradation products were the findings that plasma fibronectin is known to coprecipitate with fibrinogen in the cold (6, 7) , that loss ofpericellular matrix fibronectin is associated with malignant transformation of mesenchyme-derived cells (8) , that secretion ofplasminogen activator is associated with malignant transformation and invasive growth (9, 10) , and that fibrin (or fibrinogen, or both) split products are found in circulation in malignancies (11, 12) . The results of the present study show that potent TEF activity is associated with defined fragments of purified human plasma fibronectin digested with plasmin (EC 3.4.21.7) or with the major tissue proteinase cathespin G (EC 3.4.21.20). In contrast, fibrinogen or its degradation products had no TEF.
MATERIALS AND METHODS
Fibronectin and Its Proteolytic Fragments. Fibronectin was purified from human plasma by affinity chromatography under nondenaturing conditions as described (13) . In NaDodSOJ polyacrylamide gel electrophoresis, the purified chemically reduced protein showed, depending on the amount applied, either a doublet of polypeptide bands or a single band of M, 220,000. In two-dimensional immunoelectrophoresis against polyvalent antibodies to human plasma proteins, the purified fibronectin gave only one immunoprecipitate arch, which was identical with that obtained with anti-fibronectin antibodies. The purified fibronectin did not show any contamination with fibrinogen or plasma transglutaminase as judged by immunoelectrophoresis against specific antisera. Reduced and alkylated fibronectin was prepared according to Konigsberg (14) by using 8 M urea/10 mM dithiothreitol/100 mM N-ethylmaleimide.
Before analyses, the preparation was dialyzed against 1 mM phosphate buffer (pH 6.8).
The plasminolytic digestion of fibronectin was performed by mixing the purified protein with human plasmin (15 To separate gelatin-binding fragments from other peptides, the proteolytic digests were mixed with 1 vol of 50% (wt/vol) gelatin-Sepharose, prepared as described (13), in 50 mM Tris HCl, pH 7.5/5 mM benzamidine/0.02% sodium azide.
The mixture was rotated in an end-over mixer for 6'hr at room temperature and then applied to a column (10 x 0.8 cm); after stabilization of the column bed, the flow-through was collected (gelatin-nonbinding fraction). The elution ofthe gelatin-binding fraction was carried out with 1 M arginine (13) in the Tris/benzamidine/azide buffer. Both fractions were dialyzed at room temperature against PjNaC(l before analysis.
Fibrinogen and Its Plasminolytic Fraction. Commercially available.human fibrinogen (Kabi) was purified by passing it through gelatin-Sepharose as above, but this time to remove the contaminating fibronectin. The preparation gave, when chemically reduced, a triplet of bands corresponding to the a, 3 ,B and y chains offibrinogen in NaDodSOjpolyacrylamide gel electrophoresis and reacted in double-diffusion precipitation tests with anti-fibrinogen but not with anti-fibronectin. The .plasminolytic digestion of purified fibrinogen was performed in the same experimental conditions as described for fibronectin. The digest, according to analysis by NaDodSO4polyacryl-amide gel electrophoresis in reducing conditions, was enriched in the fibrinogen fragments D and E (18).
NaDodSOQlPolyacrylamide Gel Electrophoresis. Polyacrylamide gel electrophoresis in the presence of NaDodSO4 was by~the method of Laemmli (19) with vertical slab gels. The acrylamide concentration was 3.3% (wt/vol) in the spacer gel and 10% in the separating gel as indicated. Unless otherwise specified, the samples were reduced with 10% (wt/vol).2-mercaptoethanol in Laemmli's sample buffer. After electrophoresis, the gels were stained with Coomassie~brilliant blue R-250 (20) .
Purified. human plasma fibronectin, and commercially obtained high and low Mr markers (Pharmacia, Uppsala, Sweden) were used as standards.
Assay for TEF Activity. TEF assay was. as described (3) . Secondary cultures of chicken embryo fibroblasts were infected in suspension with the temperature-sensitive mutant PA 1(21) of the Schmidt-Ruppin strain of Rous sarcoma virus, at a low multiplicity of infection to give about 100 focus-forming units per terwards, the cultures were shifted to 370C for 4 hr, observed microscopically, and stained supravitally with methylene blue, which selectively stains foci of virus-transformed cells (22) . The number of foci were calculated in each plate, and TEF activity was recorded as the factor of enhancement (FE)-the ratio of the number of foci scored in triplicate test cultures to that in triplicate control cultures. Evaluation of the standard error and the statistical significance of the FE were calculated as described (23) .
Other Methods and Reagents. Double-diffusion precipitation tests were made on 1% agarose plates by the method of Ouchterlony (24) . The protein concentrations were assayed as described by Lowry et aL (25) with bovine serum albumin as standard. Gelatin (type I, porcine) and cycloheximide were from Sigma. Activated transglutaminase from human placenta was from Behringwerke (Marburg, Federal Republic of Germany). In analysis by NaDodSOjpolyacrylamide gel electrophoresis, the enzyme was >95% homogenous. One unit of transglutaminase corresponds to the enzyme activity present in 1 ml of freshly pooled whole human plasma by the enzyme assay of Folk and Cole (26) . (27) . Essentially similar results were obtained when porcine plasmin was used to digest fibronectin. Aliquots of the same digestion were also tested in TEF assay. Significant activity was found to be associated with the fragment mixtures obtained after 10 min, 30 min, 3 hr, 6 .hr, and 24 hr of incubation time ( samples, including intact fibronectin, diisopropyl fluorophosphate-treated plasmin, and buffer control, were all negative. Furthermore, the active digests had no apparent effect when added to uninfected control cultures. In order to avoid the interference with intact fibronectin, still present after short digestion, the fragment mixture obtained after 24 hr of incubation was chosen to study the dose dependence in TEF assay. Plasminolytic fragments of fibronectin were able to promote cell transformation at the lowest concentration of 750 ng/ml ( Fig.  2A) . On the other hand, intact fibronectin had no TEF activity in concentrations up to 100 ,g/ml (see Fig. 4B ). Furthermore, reduced and alkylated fibronectin was also devoid of TEF activity (Table 1) .
To exclude the possibility that our fibronectin preparations were contaminated by minute amounts of biologically active fibrinogen or its degradation products, we tested preparations of purified fibronectin-free fibrinogen and its plasminolytic fragments in TEF assay. Neither fibrinogen nor its fragments, which included different kinds of fragments D and E, had any TEF activity (Table 1) . Plasma transglutaminase, which under certain conditions is found in partially purified preparations of fibronectin (28), also gave negative results. In fact, in agreement with earlier findings (5), this enzyme inhibited virus-induced cell transformation (Table 1) .
Location of TEF Activity to the Gelatin-Binding Fragments of Fibronectin. In an attempt to identify the active fragments, the plasminolytic digests were fractionated by using gelatinSepharose affinity chromatography. The gelatin-binding fraction was enriched in peptides of Mr 180,000-190,000, and the gelatin-nonbinding fraction was enriched in peptides of Mr 31, 000 (Fig. 3) . TEF activity was only present in the gelatinbinding fraction, which was still active at 100 ng/ml (Fig. 2B) .
In another approach, the plasminolytic digest of fibronectin was mixed with gelatin and then tested in the TEF assay. Gelatin (1 ,ug) was able to block the effect of 15 ,ug of the digest (Fig. 4A ). Gelatin in itself had no activity. Intact fibronectin, when tested in similar competition experiments, was also active but much less so (Fig. 4B) .
Gelatin-binding fragments also were isolated from fibronectin digested with cathepsin G. This enzyme, purified from human leukocytes, was chosen because, unlike plasmin, it is known to produce well-defined, small-sized, gelatin-binding fragments (17) . During digestion, gelatin-binding fragments of Mr 200,000, 64,000, and 40,000 appear sequentially (17) , and after prolonged digestion the Mr 40,000 fragment is converted into a Mr 30,000 gelatin-binding fragment, as will be described in detail elsewhere. Fig. 3 gives the polypeptide pattern of gelatin-binding and gelatin-nonbinding fractions of such late digests. As shown in Fig. 2C the gelatin-binding fraction, mainly composed of the Mr 30,000 fragments (Fig. 3) , was active at doses as low as 100 ng/ml. The gelatin-nonbinding fraction was negative in all doses tested (up to 30 ,g/ml). morphological cell transformation. All activity appeared to reside in the fragments binding to denatured collagen (gelatin). This conclusion is based on use of highly purified fibronectin and on lack of detectable activity in fibrinogen, its degradation products, or in plasma transglutaminase, which are potential contaminants of fibronectin preparations. Moreover, intact fibronectin, reduced and alkylated fibronectin, and the other control reagents, specifically plasmin, cathepsin G, and gelatin, had no activity. Our conclusion gets further support from the observation that gelatin in relatively small doses was able to block the TEF activity of the proteolytic fragments. It inhibitory (5) . Both soluble and pericellular fibronectin are known to be substrates ofplasma transglutaminase (28, 29) , but whether fibronectin can augment the TIF activity of plasma transglutaminase is not known at present. However, the gelatinnonbinding fraction, which presumably contains the transglutaminase site (27) , had no TIF activity in the present assay.
We can only speculate about the mechanism of TEF activity of the gelatin-binding fragments of fibronectin. A plausible explanation would be that the dissociation ofthe different domains of intact fibronectin may give rise to fragments that have maintained an equal or increased affinity with one of the fibronectin interaction sites; the association of the fragment to one of the sites would prevent the binding of the intact fibronectin molecule, and the lack of the other domains in the fragment would prevent the assembly of a normal pericellular matrix.
The low doses of fibronectin degradation products (100 ng/ ml or 3 nM) needed for TEF activity might suggest involve- ment of hormone-type or enzymatic mechanism of action. Because the digests were treated with diisopropyl fluorophosphate or phenylmethylsulfonyl fluoride and the effect was obtained in the presence of calf serum, it seems unlikely that the active fragments had serine-protease activity themselves. Moreover, no plasminogen-dependent caseinolytic activity has been found in the active fractions (unpublished observations). However, there is evidence, albeit indirect that plasminogen activator may act on substrates other than plasminogen and that these effects may be involved in virus-induced cell transformation (30) . Furthermore, some of the fractions obtained from the plasma cryoprecipitate ofcancer patients have both plasminogen activator and TEF activity (31) . Thus, the possible relationship to plasminogen activators of (i) gelatin-binding fibronectin fragments and (ii) TEF activity in the culture medium oftransformed cells (1) and in plasma cryoprecipitates of cancer patients (3) needs further study. Since transformation-enhancing factors detectable by the present TEF assay are produced by virus-transformed cells in culture, the possible active role offibronectin degradation products in the transformation process might be considered.
Elevated levels of fibrinopeptides (11) and of Mr 190,000 DNA-binding proteins recognized by fibronectin antibodies (32) have been detected in tumor patient plasma and serum, respectively. These findings have been thought to be due to the increase in coagulation disorders and in proteolytic events associated with malignancy. By considering that proteolytic fragments of fibronectin but not of fibrinogen show TEF activity in vitro, it seems possible that such fragments might be responsible, at least partially, for the TEF activity detected in plasma cryoprecipitate of tumor patients. That this indeed may be the case is suggested by our observation (unpublished data) that the TEF activity ofthe cryoprecipitates is selectively bound to gelatin-Sepharose.
